CMSC Poster Gives Demographic Insights for Phase 3 PERSEUS Study of Tolebrutinib
CMSC Live: 2025 Annual Meeting Day 1
Tracking Therapeutic Progress of Gene-Editing Agent PBGENE-DMD for Duchenne Muscular Dystrophy
Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population